Research literacy

Why Evidence Quality Differs Across Peptides

Approved peptide drugs have Phase 3 programmes and labels. Many research-chemical names have rodent literature and a withdrawn compounding nomination. That is a difference in the public record, not a ranking Therapept invented.

Therapept EditorialUpdated 12 September 20266 min readReviewed by Therapept Editorial

Compare the tesamorelin file (NEJM interventional trial, BLA, WADA listing) with the selank file (originating-programme review, FDA withdrawn nomination). The landscape is built so that difference is visible as class counts, not as a 0–100.

Sources

Falutz et al., N Engl J Med (2007)
FDA — Certain bulk drug substances for use in compounding may present significant safety risks

This article is informational. It is not medical, legal or financial advice. Editorial policy · Report a correction